Who is sponsoring NCT04933344?

NCT04933344 is sponsored by Hospices Civils de Lyon.

What drugs are being tested in NCT04933344?

Interventions in NCT04933344: patients having had BJI or PJI treated with daptomycin.

What condition does NCT04933344 study?

NCT04933344 studies Dactinomycin Adverse Reaction, Bone and Joint Infection.

Is NCT04933344 still recruiting?

NCT04933344 is currently status unknown. Last updated 6 May 2022.

Last reviewed 2022-05-06 · How we verify

NCT04933344: PKTOXDAP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections

Status unknown Last updated 6 May 2022

What this trial tests

trial testing patients having had BJI or PJI treated with daptomycin in Dactinomycin Adverse Reaction in 1,130 participants. Status unknown.

Timeline

15 June 2021

Primary endpoint
1 March 2022

1 July 2022

Quick facts

Lead sponsor	Hospices Civils de Lyon
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,130
Start date	15 June 2021
Primary completion	1 March 2022
Estimated completion	1 July 2022
Sites	1 location across France

Drugs / interventions tested

patients having had BJI or PJI treated with daptomycin

Conditions studied

Dactinomycin Adverse Reaction — all drugs for Dactinomycin Adverse Reaction →
Bone and Joint Infection — all drugs for Bone and Joint Infection →

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

18 and older, any sex, with Dactinomycin Adverse Reaction or Bone and Joint Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04933344 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
Last refreshed: 6 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04933344.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing